In light of the superior sensitivity of newer PET tracers targeting PSMA to detect smaller lesions, even at low PSA levels [23], choline PET/CT is largely being replaced by PSMA PET/CT to localize oligorecurrent prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.